Menu
Recruiting NCT05815628

Next-Generation-Sequencing Approach to Neutropenic Sepsis

Observational Febrile Neutropenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DISQVER.
Who it may be relevant to
Registry conditions: Febrile Neutropenia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.

Detailed description

The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER (Platform for digital pathogen diagnostics from Noscendo GmbH) in neutropenic patients with FN (Febrile neutropenia) is to provide further evidence of the efficacy of an NGS (Next-generation seqzencing)-based approach for detecting bloodstream infection in neutropenic patients.

Interventions

  • Diagnostic test DISQVER
    NGS based infection diagnosis

Primary outcome measures

  • Evaluation of the performance of a NGS-based [Time frame: Baseline]
Secondary outcome measures (1)
  • Average process time for NGS-based measurements [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years
  • Informed consent
  • Neutropenia defined as <500 ANC (Absolute neutrophil Count)/µl or <1000 WBC (White bloddcell Count)/µl if ANC is not available
  • Fever (with an onset < 24h) or Sepsis (with an onset <24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.

Exclusion criteria

  • Age < 18 years
  • Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
  • Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
  • Death is deemed imminent and inevitable

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Germany · 6 centers
  • University Hospital of Cologne — Cologne
  • Hospital Dessau — Dessau
  • University Hospital of Essen — Essen
  • University Hospital of Frankfurt — Frankfurt am Main
  • University Hospital of Leipzig — Leipzig
  • University Hospital of Magdeburg — Magdeburg

Identifiers

NCT: NCT05815628 · NEXUS-5058

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗